Pelvic floor dysfunction and obesity.

Detrusor overactivity (DO) Lower urinary tract symptoms (LUTS) Obesity Overactive bladder symptoms (OAB) Overweight Pelvic floor dysfunction (PFD) Urinary incontinence

Journal

Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 07 05 2023
revised: 27 06 2023
accepted: 06 07 2023
medline: 11 9 2023
pubmed: 5 8 2023
entrez: 4 8 2023
Statut: ppublish

Résumé

Obesity is a growing condition within the society and more patients, who have underlying obesity, are presenting with lower urinary tract symptoms (LUTS) and pelvic floor dysfunction (PFD). The effect of obesity on general health has been well documented, and its impact on the cardiovascular, endocrine, and musculoskeletal systems has been extensively studied. There is now a growing body of evidence on the effects of obesity on the female urogenital system. It seems to influence the prevalence, presentation, assessment, management, and outcome of various types of LUTS and PFD. A holistic approach is needed to assess and manage these patients. A clear understanding of the functions of the pelvic floor and the way it can be affected by obesity is essential in providing holistic care to this group. A frank discussion about patient weight is required in the clinics handling PFD. A multimodal approach to weight loss would help improve PFD symptoms and progression. Patients with obesity should still be offered standard treatment options for all PFDs and should not be forced to lose weight as a prerequisite before starting treatment. However, they should also be made aware of the impediments that being overweight adds to their care and their expectations should be managed accordingly.

Identifiants

pubmed: 37541114
pii: S1521-6934(23)00097-4
doi: 10.1016/j.bpobgyn.2023.102389
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102389

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest None to declare.

Auteurs

Chioma Chilaka (C)

Birmingham Women's Hospital, Birmingham, UK. Electronic address: Chioma.chilaka@nhs.net.

Philip Toozs-Hobson (P)

Birmingham Women's Hospital, Birmingham, UK. Electronic address: p.toozs-hobson@nhs.net.

Victor Chilaka (V)

Women's Wellness and Research Centre, Hamad Medical Corporation, Doha, Qatar. Electronic address: vnchilaka@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH